In this downloadable slideset from a symposium conducted at the NCCN 10th Annual Congress: Hematologic Malignancies™, a group of expert faculty explore the current data and provide their recommendations for 4 CLL cases:
1: Managing Otherwise Healthy Patients with CLL
2: Treatment Considerations for a Frail Patient with CLL
3: Managing Treatment-Related Symptoms
4: An Elderly Patient with Relapsed CLL and Clonal Evolution
Co-Chairs:
William G. Wierda, MD, PhD
Andrew D. Zelenetz, MD, PhD
Faculty:
Jacqueline Barrientos, MD
Jennifer R. Brown, MD, PhD
Steven E. Coutre, MD
Thomas J. Kipps, MD
The slideset includes consideration of the following treatments plus comparative Progression Free Survival (PFS) and Overall Survival (OS) for many of the new therapies as monotherapies and with mAbs from a range of clinical trials including CLL8 (FCR vs FC), CLL10 (FCR vs BR), CLL11 (Obinutuzumab), PROLONG (Ofatumumab Maintenance vs Obsereved in Relapsed CLL) and RESONATE-17 (Single-agent ibrutinib in del17p CLL/SLL).
Treatment options covered include:
Bendamustine and Rituximab (BR)
Chlorambucil + CD20 monoclonal Antibody (mAb)
Chlorambucil ± Ofatumumab
Fludarabine, Cyclophosphamide, and Rituximab (FCR)
Ibrutinib (BTK inhibitor)
Idelalisib (PI3K inhibitor) and Rituximab
Lenalidomide
Obinutuzumab and Chlorambucil
Rituximab and Chlorambucil
Venetoclax (Second Generation BCL-2 inhibitor)
Venetoclax + Rituximab
and of course.. Watch and Wait
Patients taking Idelalisib will be most interested in the information on the typical onset times of self-limiting and severe diarrhoea/colitis and how it may be controlled with Budesonide (slides 70 - 72) and transanimase elevations - liver function ALT or AST elevations (slides 73 - 75), Pneumonitis (slide 77).
The slideset (100 slides) is available from ClinicalOptions (free registration)
clinicaloptions.com/Oncolog...
Neil
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'
News about V+O and Acalabrutinib from EHA
